Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Connexin expression in nonneoplastic human prostate epithelial cells.

Francesca Saladino1, Giuseppe Carruba, Salmaan T A Quader

  • 1Department of Experimental Oncology and Clinical Application, University Medical School, Palermo, Italy. lucashbl@unipa.it

Annals of the New York Academy of Sciences
|July 4, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stereotactic body radiotherapy for non-spinal bone oligometastases: a mono-institutional experience.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Between hope and uncertainty: the elusive evidence on hyperbaric oxygen therapy and radiotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Adjuvant radiotherapy for papillary tumor of the pineal region: a case report with a narrative review of the literature.

International cancer conference journal·2025
Same author

Adjuvant radiotherapy treatment of chordoid glioma: a case report with a literature review.

Frontiers in oncology·2025
Same author

Stereotactic Body Radiotherapy for the Treatment of Oligometastases Located in the Peritoneum or in the Abdominal Wall: Preliminary Results from a Mono-Institutional Analysis.

Journal of personalized medicine·2025
Same author

Preferred Imaging for Target Volume Delineation for Radiotherapy of Recurrent Glioblastoma: A Literature Review of the Available Evidence.

Journal of personalized medicine·2024

Connexin (Cx) protein expression differs between normal and cancerous prostate cells. Cx43 and Cx32 levels are inversely related, impacting cell communication and potentially influencing prostate cancer development.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Gap-junction proteins, connexins (Cx), facilitate intercellular communication.
  • Differential expression of connexins is implicated in various cellular processes, including cancer.

Purpose of the Study:

  • To investigate the differential expression of connexins Cx43, Cx32, and Cx26 in human prostate epithelial cells.
  • To determine the relationship between connexin expression and cellular tumorigenicity.

Main Methods:

  • Western blot analysis was used to assess connexin expression levels.
  • Treatment with forskolin and estrone was applied to evaluate their effects on connexin expression.

Main Results:

  • Cx43 was highly expressed in nontumorigenic cells (RWPE-1, WPEI-10), while Cx32 predominated in tumorigenic cells (RWPE-2, WPEI-7).

Related Experiment Videos

  • Forskolin and estrone modulated Cx43 and Cx32 expression differently across cell lines, generally increasing Cx43 in nontumorigenic cells and Cx32 in tumorigenic cells.
  • A significant inverse relationship was observed between Cx43 and Cx32 expression levels, with a higher Cx43 to Cx32 ratio in nontumorigenic cells.

    • Conclusions:

    • Connexin expression patterns, particularly the ratio of Cx43 to Cx32, are distinct between normal and cancerous prostate epithelial cells.
    • Modulation of connexin expression by agents like forskolin and estrone may influence gap junctional intercellular communication (GJIC).
    • Further research is warranted to explore the therapeutic potential of agents that alter the Cx43 to Cx32 ratio for restoring GJIC in prostate cancer systems.